-- In 5 clinical studies involving 968 older men and postmenopausal women with and without muscle wasting...
--Reached agreement with FDA on single Phase 3 clinical trial design to expand treatment population to include...
MIAMI, FL, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage...
--Overall response rates of 12.5% are observed in the enobosarm group in a heavily pretreated population versus...
MIAMI, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical...
Company receives further regulatory clarity from FDA on Phase 3 ENABLAR-2 study. Potential for enobosarm +/...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.